1. Home
  2. NODK vs ENGN Comparison

NODK vs ENGN Comparison

Compare NODK & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NODK
  • ENGN
  • Stock Information
  • Founded
  • NODK 1946
  • ENGN 1999
  • Country
  • NODK United States
  • ENGN Canada
  • Employees
  • NODK N/A
  • ENGN N/A
  • Industry
  • NODK Property-Casualty Insurers
  • ENGN
  • Sector
  • NODK Finance
  • ENGN
  • Exchange
  • NODK Nasdaq
  • ENGN Nasdaq
  • Market Cap
  • NODK 309.9M
  • ENGN 317.6M
  • IPO Year
  • NODK 2017
  • ENGN N/A
  • Fundamental
  • Price
  • NODK $14.97
  • ENGN $7.03
  • Analyst Decision
  • NODK
  • ENGN Strong Buy
  • Analyst Count
  • NODK 0
  • ENGN 9
  • Target Price
  • NODK N/A
  • ENGN $29.78
  • AVG Volume (30 Days)
  • NODK 10.7K
  • ENGN 176.0K
  • Earning Date
  • NODK 03-14-2025
  • ENGN 03-10-2025
  • Dividend Yield
  • NODK N/A
  • ENGN N/A
  • EPS Growth
  • NODK N/A
  • ENGN N/A
  • EPS
  • NODK N/A
  • ENGN N/A
  • Revenue
  • NODK $391,655,000.00
  • ENGN N/A
  • Revenue This Year
  • NODK N/A
  • ENGN N/A
  • Revenue Next Year
  • NODK N/A
  • ENGN N/A
  • P/E Ratio
  • NODK N/A
  • ENGN N/A
  • Revenue Growth
  • NODK 22.91
  • ENGN N/A
  • 52 Week Low
  • NODK $13.16
  • ENGN $4.42
  • 52 Week High
  • NODK $17.24
  • ENGN $18.40
  • Technical
  • Relative Strength Index (RSI)
  • NODK 46.09
  • ENGN 50.46
  • Support Level
  • NODK $14.34
  • ENGN $6.20
  • Resistance Level
  • NODK $15.41
  • ENGN $7.70
  • Average True Range (ATR)
  • NODK 0.26
  • ENGN 0.84
  • MACD
  • NODK 0.08
  • ENGN -0.02
  • Stochastic Oscillator
  • NODK 58.88
  • ENGN 54.19

About NODK NI Holdings Inc.

NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: